IL83301A - 11beta-(4-isopropenylphenyl)-estra-4,9-dienes,processes for the preparation thereof,and pharmaceutical compositions containing same - Google Patents

11beta-(4-isopropenylphenyl)-estra-4,9-dienes,processes for the preparation thereof,and pharmaceutical compositions containing same

Info

Publication number
IL83301A
IL83301A IL83301A IL8330187A IL83301A IL 83301 A IL83301 A IL 83301A IL 83301 A IL83301 A IL 83301A IL 8330187 A IL8330187 A IL 8330187A IL 83301 A IL83301 A IL 83301A
Authority
IL
Israel
Prior art keywords
hydrogen atom
isopropenylphenyl
estra
dienes
group
Prior art date
Application number
IL83301A
Other languages
English (en)
Other versions
IL83301A0 (en
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL83301A0 publication Critical patent/IL83301A0/xx
Publication of IL83301A publication Critical patent/IL83301A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
IL83301A 1986-07-25 1987-07-23 11beta-(4-isopropenylphenyl)-estra-4,9-dienes,processes for the preparation thereof,and pharmaceutical compositions containing same IL83301A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863625315 DE3625315A1 (de) 1986-07-25 1986-07-25 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate

Publications (2)

Publication Number Publication Date
IL83301A0 IL83301A0 (en) 1987-12-31
IL83301A true IL83301A (en) 1991-09-16

Family

ID=6306037

Family Applications (1)

Application Number Title Priority Date Filing Date
IL83301A IL83301A (en) 1986-07-25 1987-07-23 11beta-(4-isopropenylphenyl)-estra-4,9-dienes,processes for the preparation thereof,and pharmaceutical compositions containing same

Country Status (20)

Country Link
US (2) US4814327A (xx)
EP (1) EP0254670B1 (xx)
JP (1) JPH0822871B2 (xx)
CN (1) CN1026324C (xx)
AT (1) ATE48003T1 (xx)
AU (1) AU602521B2 (xx)
CA (1) CA1289944C (xx)
DD (1) DD263532A5 (xx)
DE (2) DE3625315A1 (xx)
DK (1) DK162101C (xx)
ES (1) ES2014034B3 (xx)
FI (2) FI85274C (xx)
GR (2) GR890300034T1 (xx)
HU (1) HU196829B (xx)
IE (1) IE60316B1 (xx)
IL (1) IL83301A (xx)
NO (2) NO168891C (xx)
NZ (1) NZ221185A (xx)
PT (1) PT85385B (xx)
ZA (1) ZA875518B (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) * 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
BE1004905A4 (fr) * 1987-12-30 1993-02-23 Roussel Uclaf Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
WO1990002781A1 (en) * 1988-09-16 1990-03-22 Lithium Corporation Of America Thermally stable, reactive organometallic compositions containing copper
US5316856A (en) * 1988-12-03 1994-05-31 Ngk Spark Plug Co., Ltd. Silicon nitride base sintered body
KR970005888B1 (ko) * 1989-01-12 1997-04-21 닛뽕 도꾸슈 도오교오 가부시끼가이샤 질화규소에 기초한 소결체
JP3202224B2 (ja) * 1989-08-04 2001-08-27 シエーリング アクチエンゲゼルシヤフト １１β―アリール―ゴナ―４，９―ジエン―３―オン、その製造方法及びそれを含有する調剤学的調製剤
US5100575A (en) * 1989-09-08 1992-03-31 Fmc Corporation Thermally stable, reactive organometallic compositions containing copper
FR2659233B1 (fr) * 1990-03-06 1994-01-21 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques chez les animaux d'elevage.
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
ES2106616T3 (es) * 1994-05-19 1997-11-01 Akzo Nobel Nv Derivados de 11,21-bisfenilo-19-nor-pregnanos.
DE4434488A1 (de) * 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6090798A (en) * 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
KR20010074814A (ko) 1998-08-11 2001-08-09 추후제출 항진균제로서 에스트로겐 화합물의 용도
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
CN1117759C (zh) * 1999-09-02 2003-08-13 上海中西药业股份有限公司 甾体化合物,其制备方法和其药物组合物及其应用
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
WO2004078709A2 (en) * 2003-02-28 2004-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES
EP1643981A2 (en) * 2003-06-20 2006-04-12 Viral Genomix, Inc. Antiviral compositions and methods of using the same
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
WO2007109312A2 (en) 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
JP2010507685A (ja) 2006-10-24 2010-03-11 レプロス セラピューティクス インコーポレイティド 子宮内膜増殖を抑制するための組成物および方法
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
AU2010348967C1 (en) 2010-03-22 2016-04-28 Allergan pharmaceuticals International Ltd. Compositions and methods for non-toxic delivery of antiprogestins
WO2011150209A1 (en) 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
AU2016226451B2 (en) 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
JP6754533B2 (ja) 2015-03-30 2020-09-16 コーセプト セラピューティクス， インコーポレイテッド 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用
EP3335043B1 (en) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
AU2021400069A1 (en) 2020-12-18 2023-07-06 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377419A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3205686A1 (de) * 1982-02-17 1983-08-25 Robert Bosch Gmbh, 7000 Stuttgart Hoergeraet
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3231827A1 (de) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-17(alpha)-alkinyl-17ss-hydroxy-4,9(10)- estradien-3-on-derivate, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0116974B1 (de) * 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
CN1026324C (zh) 1994-10-26
ES2014034B3 (es) 1990-06-16
FI85274C (fi) 1992-03-25
NZ221185A (en) 1989-05-29
DK162101C (da) 1992-02-24
NO168891C (no) 1992-04-15
IL83301A0 (en) 1987-12-31
CN87105307A (zh) 1988-05-11
GR3000269T3 (en) 1991-03-15
JPH0822871B2 (ja) 1996-03-06
HU196829B (en) 1989-01-30
DE3760995D1 (en) 1989-12-21
US4814327A (en) 1989-03-21
NO873117D0 (no) 1987-07-24
DK387187A (da) 1988-01-26
EP0254670A1 (de) 1988-01-27
HUT44272A (en) 1988-02-29
AU7621887A (en) 1988-01-28
JPS6335594A (ja) 1988-02-16
ATE48003T1 (de) 1989-12-15
FI913387A0 (fi) 1991-07-12
ZA875518B (en) 1988-03-30
NO873117L (no) 1988-01-26
PT85385A (de) 1987-08-01
NO167864B (no) 1991-09-09
FI873001A0 (fi) 1987-07-07
FI85274B (fi) 1991-12-13
DE3625315A1 (de) 1988-01-28
NO880742L (no) 1988-01-26
NO168891B (no) 1992-01-06
GR890300034T1 (en) 1989-04-12
DK387187D0 (da) 1987-07-24
DK162101B (da) 1991-09-16
IE872017L (en) 1988-01-25
PT85385B (pt) 1990-04-30
IE60316B1 (en) 1994-06-29
NO167864C (no) 1991-12-18
US5089488A (en) 1992-02-18
CA1289944C (en) 1991-10-01
AU602521B2 (en) 1990-10-18
FI873001A (fi) 1988-01-26
DD263532A5 (de) 1989-01-04
NO880742D0 (no) 1988-02-19
EP0254670B1 (de) 1989-11-15

Similar Documents

Publication Publication Date Title
IL83301A (en) 11beta-(4-isopropenylphenyl)-estra-4,9-dienes,processes for the preparation thereof,and pharmaceutical compositions containing same
HUT52112A (en) Process for producing 11beta-4,9,15-estratriene derivatives and pharmaceutical compositions comprising such compounds
GB8328073D0 (en) Chemical compounds
ES482112A1 (es) Procedimiento de preparacion de nuevos derivados de 3,20- dioxo-4,9-dieno-21-hidroxilo-esteroides.
MY103945A (en) Novel antiarrhythmic agents i
ES8400427A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-piperazino pirimidina.
NZ221137A (en) 14,17b-ethano-14b-estratrienes and pharmaceutical compositions
DE3261515D1 (en) Benzopyranyl ethers, process for their preparation and medicine containing those compounds and intermediates
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
IL59479A0 (en) New 7-alkylated steroid derivatives,process for preparing them, their use as a medicament and the pharmaceutical compositions containing them
ES8308890A1 (es) Procedimiento para la preparacion de cetales de 3'-deshidro -cardenolido-tridigitoxosidos.
DE3262706D1 (en) Oximes of 3"'-dehydro-cardenolide-tridigitoxosides, process for their preparation and their use as medicaments
GB2022583A (en) New ionic polyiodo benzene derivatives useful as X-ray contrast media

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees